Bottom line
XBI vs BBC: the short answer
XBI (State Street(R) SPDR(R) S&P(R) Biotech ETF) and BBC (Virtus Biotech Clinical Trials ETF) are quite different portfolios: only about 16% of their top holdings (by weight) are shared.
XBI is cheaper at 0.35% vs 0.65% — a difference of $30 a year per $10,000 invested.
Over five years, XBI returned −2.7% a year vs −4.3% for BBC.
Updated Nov 19, 2026
XBI vs BBC side by side
| XBI | BBC | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | SPDR (State Street) | Virtus |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.35% | 0.65% |
| Annual cost per $10k | $35 | $65 |
| 10-yr cost on $10k (prospectus) | $443 | $810 |
| Max front load | None | None |
| 12b-1 fee | 0% | — |
| 1-yr return | +35.8% | +63.8% |
| 5-yr return (annualized) | −2.7% | −4.3% |
| 10-yr return (annualized) | +5.8% | +3.3% |
| Best quarter | +44.4% | +59.4% |
| Worst quarter | −26.2% | −34.5% |
| Net assets (fund) | $10.7B | $46.4M |
| Number of holdings | 161 | 132 |
| Portfolio turnover | 71% | 53% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | XBI | BBC | Difference |
|---|---|---|---|
| 2025 | +35.8% | +63.8% | −28.0% |
| 2024 | +1.1% | −0.9% | +2.0% |
| 2023 | +7.5% | −1.6% | +9.1% |
| 2022 | −25.8% | −35.4% | +9.6% |
| 2021 | −20.5% | −22.4% | +1.8% |
| 2020 | +48.2% | +30.8% | +17.4% |
| 2019 | +32.2% | +62.6% | −30.4% |
| 2018 | −14.9% | −17.5% | +2.6% |
| 2017 | +43.7% | +55.6% | −11.9% |
| 2016 | −15.4% | −36.5% | +21.1% |
Source: Fund prospectus bar charts
Holdings overlap
5 of XBI's top 25 holdings also appear in BBC's top 25.
| Holding | XBI | BBC |
|---|---|---|
| Apogee Therapeutics Inc | 1.49% | 1.02% |
| Oruka Therapeutics Inc | 1.38% | 0.93% |
| Erasca Inc | 1.27% | 0.87% |
| SELLAS Life Sciences Group Inc | 1.19% | 0.86% |
| Dianthus Therapeutics Inc | 1.18% | 0.87% |
Source: SEC Form N-PORT
XBI top 10
- State Street Global Advisors — 5.87%
- Apogee Therapeutics Inc — 1.49%
- Moderna Inc — 1.41%
- Twist Bioscience Corp — 1.41%
- Oruka Therapeutics Inc — 1.38%
- Kymera Therapeutics Inc — 1.36%
- Viking Therapeutics Inc — 1.30%
- Praxis Precision Medicines Inc — 1.29%
- Erasca Inc — 1.27%
- Revolution Medicines Inc — 1.20%
BBC top 10
- Dreyfus Government Cash Manage — 3.48%
- First Tracks Biotherapeutics Inc — 1.67%
- Mbx Biosciences Inc — 1.24%
- Ataibeckley Inc — 1.23%
- Monopar Therapeutics Inc — 1.21%
- Definium Therapeutics Inc — 1.18%
- Xencor Inc — 1.10%
- Zenas Biopharma Inc — 1.06%
- Uniqure Nv — 1.06%
- Apogee Therapeutics Inc — 1.02%
FAQ
What is the difference between XBI and BBC?
Which is cheaper, XBI or BBC?
Should I own both XBI and BBC?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.